Cancer Pain Market - 2023-2033
Description
Cancer Pain Market Overview:
The Cancer Pain Market was valued at US$ 7.45 Billion in 2023 and is anticipated to reach US$ 12.45 Billion by 2033, at a CAGR of 0.059 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Pain Market.
This report delivers a comprehensive overview of the Cancer Pain Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Pain Market. The Cancer Pain Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
Cancer Pain Market Scope:
Key Players
• CK Life Sciences (WEX Pharmaceuticals Inc)
• Mundipharma International.
• Orexo AB
• DAIICHI SANKYO COMPANY, LIMITED.
• Hisamitsu Pharmaceutical Co., Inc.
• Pfizer Inc.
• Grünenthal
• Teva Pharmaceutical Industries Ltd.
• Galena Biopharma
• Meda Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• Dogwood Therapeutics, Inc.
Major Highlights
This report delivers a comprehensive overview of the Cancer Pain Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Pain Market. The Cancer Pain Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Cancer Pain Market was valued at US$ 7.45 Billion in 2023 and is anticipated to reach US$ 12.45 Billion by 2033, at a CAGR of 0.059 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cancer Pain Market.
This report delivers a comprehensive overview of the Cancer Pain Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Pain Market. The Cancer Pain Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
Cancer Pain Market Scope:
Key Players
• CK Life Sciences (WEX Pharmaceuticals Inc)
• Mundipharma International.
• Orexo AB
• DAIICHI SANKYO COMPANY, LIMITED.
• Hisamitsu Pharmaceutical Co., Inc.
• Pfizer Inc.
• Grünenthal
• Teva Pharmaceutical Industries Ltd.
• Galena Biopharma
• Meda Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• Dogwood Therapeutics, Inc.
Major Highlights
This report delivers a comprehensive overview of the Cancer Pain Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cancer Pain Market. The Cancer Pain Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
223 Pages
- 1. Market Introduction and Scope
- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope
- 2. Executive Insights and Key Takeaways
- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Drug Class
- 2.4. Snippet by Application
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by End-User
- 2.7. Snippet by Region
- 3. Dynamics
- 3.1. Impacting Factors
- 3.1.1. Drivers
- 3.1.1.1. Rising Cancer Incidence
- 3.1.1.2. Advancements in Pain Management Therapies
- 3.1.1.3. Rising Healthcare Expenditure and Government Support
- 3.1.2. Restraints
- 3.1.2.1. Regulatory Challenges and Opioid Restrictions
- 3.1.2.2. Side Effects and Safety Concerns
- 3.1.2.3. High Cost of Advanced Therapies
- 3.1.3. Opportunity
- 3.1.3.1. Emergence of Breakthrough Therapies
- 3.1.3.2. Integration of Multidisciplinary Approaches
- 3.1.3.3. Adoption of Digital Health and Remote Monitoring
- 3.1.4. Impact Analysis
- 4. Strategic Insights and Industry Outlook
- 4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with the largest-selling Brand
- 4.1.3. Market leaders with established Product
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. Asia Pacific
- 4.3.4. South America
- 4.3.5. Middle East & Africa
- 4.4. Porter’s Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.11. Pricing Analysis and Price Dynamics
- 5. Global Cancer Pain Market, By Drug Class
- 5.1. Introduction
- 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 5.1.2. Market Attractiveness Index By Drug Class
- 5.2. Opioids*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. NSAIDs
- 5.4. Morphine
- 5.5. Non-Opioids
- 5.6. Nerve Blockers
- 5.7. Others
- 6. Global Cancer Pain Market, By Application
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 6.1.2. Market Attractiveness Index By Application
- 6.2. Lung Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Colorectal Cancer
- 6.4. Breast Cancer
- 6.5. Prostate Cancer
- 6.6. Blood Cancer
- 6.7. Others
- 7. Global Cancer Pain Market, By Route of Administration
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index By Route of Administration
- 7.2. Oral*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Parenteral
- 7.4. Others
- 8. Global Cancer Pain Market, By End-User
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
- 8.2. Hospitals *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Homecare
- 8.4. Specialty Clinics
- 8.5. Others
- 9. Global Cancer Pain Market, By Regional Market Analysis and Growth Opportunities
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.7.1. U.S.
- 9.2.7.2. Canada
- 9.2.7.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.7.1. Germany
- 9.3.7.2. U.K.
- 9.3.7.3. France
- 9.3.7.4. Spain
- 9.3.7.5. Italy
- 9.3.7.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.7.1. Brazil
- 9.4.7.2. Argentina
- 9.4.7.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.7.1. China
- 9.5.7.2. India
- 9.5.7.3. Japan
- 9.5.7.4. South Korea
- 9.5.7.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10. Competitive Landscape and Market Positioning
- 10.1. Competitive Overview and Key Market Players
- 10.2. Market Share Analysis and Positioning Matrix
- 10.3. Strategic Partnerships, Mergers & Acquisitions
- 10.4. Key Developments in Product Portfolios and Innovations
- 10.5. Company Benchmarking
- 11. Company Profiles
- 11.1. CK Life Sciences (WEX Pharmaceuticals Inc) *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio
- 11.1.2.1. Product Description
- 11.1.2.2. Product Key Performance Indicators (KPIs)
- 11.1.2.3. Historic and Forecasted Product Sales
- 11.1.2.4. Product Sales Volume
- 11.1.3. Financial Overview
- 11.1.3.1. Company Revenue
- 11.1.3.2. Geographical Revenue Shares
- 11.1.3.3. Revenue Forecasts
- 11.1.4. Key Developments
- 11.1.4.1. Mergers & Acquisitions
- 11.1.4.2. Key Product Development Activities
- 11.1.4.3. Regulatory Approvals, etc.
- 11.1.4.4. SWOT Analysis
- 11.2. Mundipharma International.
- 11.3. Orexo AB
- 11.4. DAIICHI SANKYO COMPANY, LIMITED.
- 11.5. Hisamitsu Pharmaceutical Co., Inc.
- 11.6. Pfizer Inc.
- 11.7. Grünenthal
- 11.8. Teva Pharmaceutical Industries Ltd.
- 11.9. Galena Biopharma
- 11.10. Meda Pharmaceuticals
- 11.11. Vertex Pharmaceuticals Incorporated
- 11.12. Dogwood Therapeutics, Inc. (LIST NOT EXHAUSTIVE )
- 12. Assumptions and Research Methodology
- 12.1. Data Collection Methods
- 12.2. Data Triangulation
- 12.3. Forecasting Techniques
- 12.4. Data Verification and Validation
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
